15% - 20% of people with chronic wounds don’t respond to standardised treatments. Personalised medical research can help.
🕐 5 minutes
There is some concern about how personalisation sits with other established medical practices like standardisation and translational medical research. Standardisation is about the creation of uniform healthcare treatments; translational medical research involves the application of experimental science to clinical medicine. Both are totally compatible with personalisation. In fact, the combination of personalised medicine, standardisation and translational medical research has the potential to take healthcare to places it’s never been before.
While process standardisation was a major breakthrough in industrial management many years ago, it was only recently introduced to the world of medicine. Standardisation, especially that which uses results from translational medical research, has already helped push healthcare to new levels. Despite some early reservations about the use of standardised treatments, results showed that in many fields, better patient outcomes were only possible by reducing medical complications. Standardisation was key. Introducing checklists in operation theatres , hospital-wide hygiene protocols , and standardised screening and prevention initiatives for cancer and cardiovascular diseases had all made huge contributions.
Medical standardisation makes its impact when it comes to improvements that benefit large populations. But we still have a long way to go in areas such as hand hygiene, surface disinfection and process optimisation in operating theatres. Continued medical research into these areas will help us address the significant challenges facing healthcare systems in relation to things like healthcare acquired infections.
Standardisation also remains important in therapeutic areas such as wound care where simple, effective and economical solutions often provide the best outcomes for people with chronic wounds. Yet, personalised treatment options are also essential to treat wounds for the estimated 15% - 20% of chronic wound patients who fail to respond to standardised therapies. Research into how these two practices overlap has only just begun, but as the cancer therapy example above shows, the results can be highly effective.
If we are to address some of the major challenges faced by today’s healthcare systems, we must stop looking at standardised medicine and personalised treatments as contradictory practices. Taken together, they can be used to go further for health by treating more people, more effectively.
Hans joined the HARTMANN GROUP as medical director in 2004. He adds the medical perspective to our product positioning and bridges medical sciences and business. His motto: Today influences what will happen in 5 years. So, let’s get started.